B cell subpopulations in the pathogenesis of rheumatoid arthritis

Akademisk avhandling

som för avläggande av medicine doktorsexamen vid Sahlgrenska akademin vid Göteborgs universitet kommer att offentligen försvaras i föreläsningssalen våning 3, Guldhedsgatan 10A, Göteborg, fredagen den 26 april 2019 kl. 9.00

av

Katrin Thorarinsdottir

Fakultetsopponent:

Docent Lisa Westerberg

Avdelningen för mikrobiologi, tumör- och cellbiologi, Karolinska institutet

Avhandlingen baseras på följande delarbeten

- I. Thorarinsdottir K*, Camponeschi A*, Cavallini N*, Grimsholm O, Jacobsson L, Gjertsson I, Mårtensson I-L. CD21^{-/low} B cells in human blood are memory cells. *Clin Exp Immunol*. 2016; 185: 252-262.
 - *These authors contributed equally to the study
- II. Thorarinsdottir K, Camponeschi A, Jonsson C, Nilsson J, Forslind K, Visentini M, Jacobsson L, Mårtensson I-L, Gjertsson I. CD21^{-/low} B cells associate with joint damage in rheumatoid arthritis patients.
 Submitted
- III. Thorarinsdottir K, Forslind K, Agelii ML, Rudin A, Jacobsson L, Mårtensson I-L, Gjertsson I. Memory B cell subsets correlate with autoantibody titers, disease activity and joint damage in untreated early rheumatoid arthritis. *In Manuscript*

INSTITUTIONEN FÖR MEDICIN

ISBN: 978-91-7833-350-9 (TRYCK) http://hdl.handle.net/2077/58499

ISBN: 978-91-7833-351-6 (PDF)

B cell subpopulations in the pathogenesis of rheumatoid arthritis

Katrin Thorarinsdottir, Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy,
University of Gothenburg, Sweden, 2019

ABSTRACT

B cell depleting therapy has proven to be an effective treatment in rheumatoid arthritis (RA), a disease characterized by the presence of autoantibodies against citrullinated proteins (ACPA) and the Fc portion of IgG (rheumatoid factor, RF). This demonstrates the vital role B cells play in the disease. The aim of this thesis was to explore the role of B cell subpopulations in the pathogenesis of RA. Our interest in a specific B cell population arose with the discovery of murine autoreactive B cells, CD21^{-/low} cells, which expressed low surface levels or lacked the complement receptor 2 (CD21). CD21 helps activate B cells, as it is a part of the B cell co-receptor complex.

In Studies I-III we analyzed B cell populations in human peripheral blood with the help of flow cytometry utilizing multiple cell markers. In Studies II-III, clinical as well as radiographic data was collected from RA patients.

In **Study I** we established that CD21^{-/low} B cells are found in human peripheral blood and discovered that in healthy donors (HDs) this B cell population is mainly composed of memory B cells (MBCs) based on their phenotype and response to combined stimuli. In **Study II** we compared the B cell populations in peripheral blood of patients with established RA and HDs. We saw a higher proportion of a CD21^{-/low} subpopulation, i.e. CD21^{-/low} CD27⁻IgD⁻ (double negative, DN) in patients with autoantibodies (ACPA/RF) compared to HDs. Additionally, the frequency of CD21^{-/low} DN cells was higher in ACPA/RF positive patients with more joint destruction compared to those with less, and the CD21^{-/low} DN population correlated positively with the level of destruction. The CD21^{-/low} DN population was highly enriched in the inflamed joints of RA patients and a third of the cells expressed RANKL, which stimulates osteoclastogenesis. In **Study III**, we compared the B cell populations in peripheral blood in newly diagnosed untreated RA patients and HDs. We observed that the proportion of CD21⁺CD27⁺ MBCs correlated positively with RF and ACPA titers. In addition, the frequency of CD21⁺DN cells and CD21^{-/low} DN MBCs correlated positively with tender joint count and joint narrowing score respectively.

joint inflammation and the CD21^{-/low} DN MBCs the joint damage. **Keywords**: Rheumatoid arthritis, B cells, CD21^{-/low} B cells, DAS28, joint destruction

In conclusion, it seems that different MBCs have different roles in RA where CD21⁺ CD27⁺ MBCs appear to drive the autoantibody response, the CD21⁺DN MBCs the

ISBN: 978-91-7833-350-9 (TRYCK) http://hdl.handle.net/2077/58499

ISBN: 978-91-7833-351-6 (PDF)